CRL
NYSE · Life Sciences Tools & Services
Charles River Laboratories
$159.19
+1.19 (+0.75%)
Financial Highlights (FY 2026)
Revenue
3.25B
Net Income
8.26M
Gross Margin
34.8%
Profit Margin
0.3%
Rev Growth
+4.6%
D/E Ratio
0.65
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 34.8% | 34.8% | 66.6% | 66.6% |
| Operating Margin | 5.6% | 5.0% | 20.0% | 22.0% |
| Profit Margin | 0.3% | 0.2% | 15.4% | 18.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 3.25B | 3.11B | 1.98B | 1.66B |
| Gross Profit | 1.13B | 1.08B | 1.32B | 1.10B |
| Operating Income | 182.31M | 156.88M | 395.10M | 365.66M |
| Net Income | 8.26M | 7.11M | 304.29M | 307.56M |
| Gross Margin | 34.8% | 34.8% | 66.6% | 66.6% |
| Operating Margin | 5.6% | 5.0% | 20.0% | 22.0% |
| Profit Margin | 0.3% | 0.2% | 15.4% | 18.6% |
| Rev Growth | +4.6% | +4.6% | +16.2% | +9.9% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 1.54B | 1.54B | 2.06B | 1.87B |
| Total Equity | 2.38B | 2.38B | 3.63B | 3.31B |
| D/E Ratio | 0.65 | 0.65 | 0.57 | 0.56 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 290.63M | 263.98M | 664.62M | 536.40M |
| Free Cash Flow | — | — | 311.82M | 266.24M |